Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CAMP4 Therapeutics Corporation (CAMP : NSDQ)

• Company Description    CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based in CAMBRIDGE, Mass. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $6.13 Daily Weekly Monthly 20 Day Moving Average: 306,317 shares Shares Outstanding: 46.88 (millions) Market Capitalization: $287.38 (millions) Beta: 0.66 52 Week High: $7.31 52 Week Low: $1.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 80.83% 81.13% 12 Week 61.74% 59.13% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE KENDALL SQUARE BUILDING 1400 WEST 3RD FLOOR - CAMBRIDGE,MA 02139 USA ph: 617-651-8867 fax: - svonderweid@lifesciadvisors.com http://www.camp4tx.com

• General Corporate Information    Officers Josh Mandel-Brehm - Chief Executive Officer and President Steven Holtzman - Chairman Kelly Gold - Chief Financial Officer James Boylan - Director Ingo Chakravarty - Director Peer Information CAMP4 Therapeutics Corporation (CORR.) CAMP4 Therapeutics Corporation (RSPI) CAMP4 Therapeutics Corporation (CGXP) CAMP4 Therapeutics Corporation (BGEN) CAMP4 Therapeutics Corporation (GTBP) CAMP4 Therapeutics Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 13463J101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 46.88 Most Recent Split Date: (:1) Beta: 0.66 Market Capitalization: $287.38 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.92 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.90 Price/Cash Flow: - Price / Sales: 75.59 EPS Growth vs. Year Ago Period: 97.73% vs. Previous Quarter: 11.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -46.89% ROE 12/31/25 - - 09/30/25 - -100.10 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -76.62 06/30/25 - -96.92 Current Ratio 12/31/25 - - 09/30/25 - 9.83 06/30/25 - 5.60 Quick Ratio 12/31/25 - - 09/30/25 - 9.83 06/30/25 - 5.60 Operating Margin 12/31/25 - - 09/30/25 - -1,404.47 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - -1,404.47 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,404.47 06/30/25 - -1,722.08 Book Value 12/31/25 - - 09/30/25 - 1.25 06/30/25 - 1.98 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.08 06/30/25 - 0.15

Powered by Zacks Investment Research ©